Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial
We investigated the impact of subcutaneous versus intravenous bortezomib in the MM5 trial of the German-Speaking Myeloma Multicenter Group which compared bortezomib, doxorubicin, and dexamethasone with bortezomib, cyclophosphamide, and dexamethasone induction therapy in newly diagnosed multiple myel...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 2015
|
| In: |
Haematologica
Year: 2015, Jahrgang: 100, Heft: 7, Pages: 964-969 |
| ISSN: | 1592-8721 |
| DOI: | 10.3324/haematol.2015.124347 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.3324/haematol.2015.124347 Verlag, Volltext: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486231/ 
|
| Verfasserangaben: | Maximilian Merz, Hans Salwender, Mathias Haenel, Elias K. Mai, Uta Bertsch, Christina Kunz, Thomas Hielscher, Igor W. Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Anna Jauch, Jens Hillengass, Marc S. Raab, Baerbel Schurich, Markus Munder, Ingo G.H. Schmidt-Wolf, Christian Gerecke, Hans-Walter Lindemann, Matthias Zeis, Katja Weisel, Jan Duerig, Hartmut Goldschmidt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1556618662 | ||
| 003 | DE-627 | ||
| 005 | 20230426153656.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 170413s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3324/haematol.2015.124347 |2 doi | |
| 035 | |a (DE-627)1556618662 | ||
| 035 | |a (DE-576)486618668 | ||
| 035 | |a (DE-599)BSZ486618668 | ||
| 035 | |a (OCoLC)1340973019 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Merz, Maximilian |d 1985- |e VerfasserIn |0 (DE-588)1023626950 |0 (DE-627)718419278 |0 (DE-576)367168251 |4 aut | |
| 245 | 1 | 0 | |a Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma |b an interim analysis from the prospective GMMG-MM5 trial |c Maximilian Merz, Hans Salwender, Mathias Haenel, Elias K. Mai, Uta Bertsch, Christina Kunz, Thomas Hielscher, Igor W. Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Anna Jauch, Jens Hillengass, Marc S. Raab, Baerbel Schurich, Markus Munder, Ingo G.H. Schmidt-Wolf, Christian Gerecke, Hans-Walter Lindemann, Matthias Zeis, Katja Weisel, Jan Duerig, Hartmut Goldschmidt |
| 264 | 1 | |c July 2015 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 13.04.2017 | ||
| 520 | |a We investigated the impact of subcutaneous versus intravenous bortezomib in the MM5 trial of the German-Speaking Myeloma Multicenter Group which compared bortezomib, doxorubicin, and dexamethasone with bortezomib, cyclophosphamide, and dexamethasone induction therapy in newly diagnosed multiple myeloma. Based on data from relapsed myeloma, the route of administration for bortezomib was changed from intravenous to subcutaneous after 314 of 604 patients had been enrolled. We analyzed 598 patients who received at least one dose of trial medication. Adverse events were reported more frequently in patients treated with intravenous bortezomib (intravenous=65%; subcutaneous=56%, P=0.02). Rates of grade 2 or more peripheral neuropathy were higher in patients treated with intravenous bortezomib during the third cycle (intravenous=8%; subcutaneous=2%, P=0.001). Overall response rates were similar in patients treated intravenously or subcutaneously. The presence of International Staging System stage III disease, renal impairment or adverse cytogenetic abnormalities did not have a negative impact on overall response rates in either group. To our knowledge this is the largest study to present data comparing subcutaneous with intravenous bortezomib in newly diagnosed myeloma. We show better tolerance and similar overall response rates for subcutaneous compared to intravenous bortezomib. The clinical trial is registered at eudract.ema.europa.eu as n. 2010-019173-16. | ||
| 700 | 1 | |a Mai, Elias K. |d 1985- |e VerfasserIn |0 (DE-588)1049182545 |0 (DE-627)781300274 |0 (DE-576)403130999 |4 aut | |
| 700 | 1 | |a Bertsch, Uta |e VerfasserIn |0 (DE-588)1026849861 |0 (DE-627)727494163 |0 (DE-576)372176224 |4 aut | |
| 700 | 1 | |a Hose, Dirk |d 1969- |e VerfasserIn |0 (DE-588)139824995 |0 (DE-627)613790308 |0 (DE-576)313431698 |4 aut | |
| 700 | 1 | |a Seckinger, Anja |d 1980- |e VerfasserIn |0 (DE-588)134177371 |0 (DE-627)562118225 |0 (DE-576)278603734 |4 aut | |
| 700 | 1 | |a Jauch, Anna |d 1959- |e VerfasserIn |0 (DE-588)1025525140 |0 (DE-627)722525362 |0 (DE-576)168357496 |4 aut | |
| 700 | 1 | |a Hillengaß, Jens |d 1974- |e VerfasserIn |0 (DE-588)124918549 |0 (DE-627)368073823 |0 (DE-576)294568298 |4 aut | |
| 700 | 1 | |a Raab, Marc-Steffen |d 1973- |e VerfasserIn |0 (DE-588)124052460 |0 (DE-627)706520998 |0 (DE-576)293998027 |4 aut | |
| 700 | 1 | |a Schurich, Bärbel |e VerfasserIn |0 (DE-588)1070073237 |0 (DE-627)823264750 |0 (DE-576)429746121 |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Haematologica |d Pavia : Ferrata Storti Foundation, 2014 |g 100(2015), 7, Seite 964-969 |h Online-Ressource |w (DE-627)814204899 |w (DE-600)2805244-4 |w (DE-576)424051125 |x 1592-8721 |7 nnas |a Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma an interim analysis from the prospective GMMG-MM5 trial |
| 773 | 1 | 8 | |g volume:100 |g year:2015 |g number:7 |g pages:964-969 |g extent:6 |a Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma an interim analysis from the prospective GMMG-MM5 trial |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3324/haematol.2015.124347 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486231/ |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20170413 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |d 50000 |e 910000PG102258023X |e 910100PG102258023X |e 50000PG102258023X |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 23 |y j | ||
| 998 | |g 1070073237 |a Schurich, Bärbel |m 1070073237:Schurich, Bärbel |d 910000 |d 913000 |e 910000PS1070073237 |e 913000PS1070073237 |k 0/910000/ |k 1/910000/913000/ |p 15 | ||
| 998 | |g 124052460 |a Raab, Marc-Steffen |m 124052460:Raab, Marc-Steffen |d 910000 |e 910000PR124052460 |k 0/910000/ |p 14 | ||
| 998 | |g 124918549 |a Hillengaß, Jens |m 124918549:Hillengaß, Jens |d 910000 |d 910100 |e 910000PH124918549 |e 910100PH124918549 |k 0/910000/ |k 1/910000/910100/ |p 13 | ||
| 998 | |g 1025525140 |a Jauch, Anna |m 1025525140:Jauch, Anna |d 910000 |d 911500 |e 910000PJ1025525140 |e 911500PJ1025525140 |k 0/910000/ |k 1/910000/911500/ |p 12 | ||
| 998 | |g 134177371 |a Seckinger, Anja |m 134177371:Seckinger, Anja |d 910000 |d 910100 |e 910000PS134177371 |e 910100PS134177371 |k 0/910000/ |k 1/910000/910100/ |p 11 | ||
| 998 | |g 139824995 |a Hose, Dirk |m 139824995:Hose, Dirk |d 910000 |d 910100 |d 50000 |e 910000PH139824995 |e 910100PH139824995 |e 50000PH139824995 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 10 | ||
| 998 | |g 1026849861 |a Bertsch, Uta |m 1026849861:Bertsch, Uta |d 910000 |d 910100 |e 910000PB1026849861 |e 910100PB1026849861 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 998 | |g 1049182545 |a Mai, Elias K. |m 1049182545:Mai, Elias K. |d 910000 |d 910100 |e 910000PM1049182545 |e 910100PM1049182545 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 1023626950 |a Merz, Maximilian |m 1023626950:Merz, Maximilian |d 910000 |d 910100 |e 910000PM1023626950 |e 910100PM1023626950 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1556618662 |e 2965173439 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.3324/haematol.2015.124347"],"eki":["1556618662"]},"name":{"displayForm":["Maximilian Merz, Hans Salwender, Mathias Haenel, Elias K. Mai, Uta Bertsch, Christina Kunz, Thomas Hielscher, Igor W. Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Anna Jauch, Jens Hillengass, Marc S. Raab, Baerbel Schurich, Markus Munder, Ingo G.H. Schmidt-Wolf, Christian Gerecke, Hans-Walter Lindemann, Matthias Zeis, Katja Weisel, Jan Duerig, Hartmut Goldschmidt"]},"physDesc":[{"extent":"6 S."}],"relHost":[{"part":{"pages":"964-969","year":"2015","issue":"7","text":"100(2015), 7, Seite 964-969","extent":"6","volume":"100"},"titleAlt":[{"title":"journal of the European Hematology Association"}],"language":["eng"],"id":{"zdb":["2805244-4"],"issn":["1592-8721"],"eki":["814204899"]},"recId":"814204899","physDesc":[{"extent":"Online-Ressource"}],"disp":"Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma an interim analysis from the prospective GMMG-MM5 trialHaematologica","type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title":"Haematologica","title_sort":"Haematologica","subtitle":"journal of the European Hematology Association : journal of the Ferrata Storti Foundation"}],"note":["Gesehen am 27.05.2022"],"pubHistory":["99.2014 -"],"origin":[{"publisherPlace":"Pavia","dateIssuedDisp":"2014-","dateIssuedKey":"2014","publisher":"Ferrata Storti Foundation"}]}],"recId":"1556618662","type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 13.04.2017"],"origin":[{"dateIssuedDisp":"July 2015","dateIssuedKey":"2015"}],"title":[{"title_sort":"Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma","subtitle":"an interim analysis from the prospective GMMG-MM5 trial","title":"Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma"}],"language":["eng"],"person":[{"given":"Maximilian","role":"aut","family":"Merz","display":"Merz, Maximilian"},{"display":"Mai, Elias K.","family":"Mai","role":"aut","given":"Elias K."},{"role":"aut","given":"Uta","family":"Bertsch","display":"Bertsch, Uta"},{"display":"Hose, Dirk","family":"Hose","role":"aut","given":"Dirk"},{"family":"Seckinger","display":"Seckinger, Anja","given":"Anja","role":"aut"},{"role":"aut","given":"Anna","family":"Jauch","display":"Jauch, Anna"},{"given":"Jens","role":"aut","display":"Hillengaß, Jens","family":"Hillengaß"},{"given":"Marc-Steffen","role":"aut","display":"Raab, Marc-Steffen","family":"Raab"},{"role":"aut","given":"Bärbel","family":"Schurich","display":"Schurich, Bärbel"},{"given":"Hartmut","role":"aut","family":"Goldschmidt","display":"Goldschmidt, Hartmut"}]} | ||
| SRT | |a MERZMAXIMISUBCUTANEO2015 | ||